Compliance RiskEpr ExposureGhg Intensity
Risk Breakdown
GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.0
EPR Exposure
6.5
Compliance Risk
10.0
HR Risk
3.0
Governance Risk
3.0
Financial Exposure
Est. Compliance Cost₹60–223 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated508.3 T
Governance
Anti-Corruption PolicyYes
Conflict of Interest PolicyYes
BRSR AssuranceAll
Assurance ProviderBureau Veritas India Pvt. Ltd.
Double Materiality
Financial Materiality5.2
Impact Materiality4.6
QuadrantFinancially Material
Supply Chain
MSME Sourcing0.1%
Lifecycle AssessmentNo
Product ReclaimYes
Material Risks
e-waste
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
GlaxoSmithKline Pharmaceuticals Limited carries a medium ESG financial risk score of 5.2/10. Primary risk drivers are compliance risk, epr exposure. Estimated annual compliance cost exposure: ₹60–223 crore.
Source: GlaxoSmithKline Pharmaceuticals Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.